Morningstar Tshawb Fawb
Tus kws tshuaj ntsuam xyuas: Bausch Health Companies Inc.
Yav tas los hu ua Valeant Pharmaceuticals, Bausch Health yog lub ntiaj teb tshwj xeeb kws tshuaj, cov neeg siv khoom noj qab haus huv, thiab cov cuab yeej siv kho mob nrog rau kev tsom mus rau cov khoom lag luam muaj npe rau kev lag luam dermatology, gastrointestinal, thiab ophthalmology. Lub tuam txhab tshaj tawm cov nyiaj tau los hauv tsib ntu: Bausch + Lomb (45% ntawm cov nyiaj tau los), Salix Pharmaceuticals (24%), thoob ntiaj teb pharma (14%), ortho dermatology (7%), thiab cov khoom sib txawv (10%). Bausch yog tus thawj coj hauv kev lag luam hauv kev saib xyuas cov neeg siv khoom pom hauv Is Nrias teb thiab Tuam Tshoj thiab yog lub tuam txhab kev saib xyuas thib plaub loj tshaj plaws los ntawm kev muag khoom hauv Tebchaws Meskas.
Tau qhov twg los: https://finance.yahoo.com/news/rbc-capital-expect-bausch-health-193210196.html